Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Products under Development by Stage of Development | 9 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Products under Development by Therapy Area | 10 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Products under Development by Indication | 11 | 2 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Products under Development by Companies | 15 | 4 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Products under Development by Universities/Institutes | 19 | 2 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Therapeutics Assessment | 21 | 5 |
| Assessment by Monotherapy/Combination Products | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 26 | 13 |
| AbbVie Inc. | 26 | 1 |
| Advenchen Laboratories, LLC | 27 | 1 |
| Aeterna Zentaris Inc. | 28 | 1 |
| Amgen Inc. | 29 | 1 |
| Astex Pharmaceuticals, Inc. | 30 | 1 |
| AstraZeneca Plc | 31 | 1 |
| Chipscreen Biosciences Ltd | 32 | 1 |
| Merck KGaA | 33 | 1 |
| Nemucore Medical Innovations, Inc. | 34 | 1 |
| Sanofi | 35 | 1 |
| Sareum Holdings Plc | 36 | 1 |
| Vertex Pharmaceuticals Incorporated | 37 | 1 |
| Vichem Chemie Research Ltd. | 38 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Drug Profiles | 39 | 21 |
| AL-8326 Drug Profile | 39 | 1 |
| AMG-900 Drug Profile | 40 | 2 |
| AT-9283 Drug Profile | 42 | 2 |
| AZD-2811 Drug Profile | 44 | 2 |
| CS-2164 Drug Profile | 46 | 1 |
| danusertib Drug Profile | 47 | 1 |
| ilorasertib Drug Profile | 48 | 2 |
| NMI-900 Drug Profile | 50 | 1 |
| SAR-156497 Drug Profile | 51 | 1 |
| SAR-3 Drug Profile | 52 | 1 |
| SAR-4 Drug Profile | 53 | 2 |
| Small Molecule to Inhibit Aurora B Kinase for Cancer Drug Profile | 55 | 1 |
| Small Molecules to Inhibit Aurora A/B Kinase for Oncology Drug Profile | 56 | 1 |
| Small Molecules to Inhibit Aurora B Kinase for Oncology Drug Profile | 57 | 1 |
| Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology Drug Profile | 58 | 1 |
| VE-465 Drug Profile | 59 | 1 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Dormant Projects | 60 | 7 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Discontinued Products | 67 | 2 |
| Aurora Kinase B (Aurora 1 or Aurora- and IPL1-Like Midbody-Associated Protein 1 or Serine/Threonine-Protein Kinase 12 or EC 2.7.11.1) Featured News &Press Releases | 69 | 10 |
| May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics | 69 | 1 |
| Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies | 70 | 1 |
| Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors | 70 | 2 |
| Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors | 72 | 1 |
| Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811 | 72 | 1 |
| Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015 | 73 | 1 |
| Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting | 74 | 1 |
| Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting | 75 | 1 |
| Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme | 75 | 1 |
| May 16, 2012: Astex Pharmaceuticals To Present Data On AT9283 At ASCO Annual Meeting | 75 | 1 |
| Jan 27, 2012: Cancer Research UK Launches Trial Of New Drug To Treat Acute Childhood Leukemia | 76 | 1 |
| Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Docetaxel For Treatment Of Non-Hodgkin s Lymphoma | 76 | 1 |
| Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Lenalidomide For Treatment Of Multiple Myeloma At ASH Annual Meeting | 77 | 1 |
| Nov 04, 2010: Astex And NCIC Clinical Trials Group Initiate Phase II Clinical Study Of AT9283 In Multiple Myeloma | 77 | 1 |
| Nov 23, 2009: Astex Granted Orphan Drug Status For AT9283 In AML In USA And Europe | 78 | 1 |
| Appendix | 79 | 2 |
| Methodology | 79 | 1 |
| Coverage | 79 | 1 |
| Secondary Research | 79 | 1 |
| Primary Research | 79 | 1 |
| Expert Panel Validation | 79 | 1 |
| Contact Us | 79 | 1 |
| Disclaimer | 80 | 1 |